FindMyRecallSubscribe
Class III: unlikely to cause harmTerminated

Sanofi-Aventis U.S. Clofarabine injection Recall

Clofarabine injection, 20 mg/20 mL, 20 mL Single-Use Vial, Rx only, Mfd by: Teva Pharma…

Sanofi-Aventis U.S. LLC · Bridgewater, NJ

Risk level
Class III
Reported by FDA
Nov 8, 2017
Recall ID
D-0056-2018
Check your lot numberHow we source this data

Summary

Sanofi-Aventis U.S. recalled Clofarabine injection starting Oct 13, 2017. The FDA classified it as Class III (unlikely to cause harm) and published enforcement report D-0056-2018 on Nov 8, 2017. Reason: Labeling: Incorrect or Missing Package Insert: authorized generic product was packaged with the incorrect insert for the brand name product Clolar (clofarabine) injection. Status: Terminated.

Why it was recalled

Labeling: Incorrect or Missing Package Insert: authorized generic product was packaged with the incorrect insert for the brand name product Clolar (clofarabine) injection.

Product description

Clofarabine injection, 20 mg/20 mL, 20 mL Single-Use Vial, Rx only, Mfd by: Teva Pharmachemle, Swensweg 5, Haarlem, The Netherlands; Mfd for: Winthrop U.S., a business of sanofi-aventis U.S. LLC, Bridgewater, NJ 08807; NDC 0955-1746-01.

Lot numbers, UPCs & expiration codes

Lot #: K5006Y02, Exp 31AUG18

Where it was sold

Nationwide in the USA

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0056-2018
Classification
Class III
Status
Terminated
Recall initiated
Oct 13, 2017
FDA report date
Nov 8, 2017
Quantity
422 vials
Recall type
Voluntary: Firm initiated
Recalling firm
Sanofi-Aventis U.S. LLC

Original FDA data

Every field from FDA enforcement report D-0056-2018, exactly as published.

Show all FDA fields
City
Bridgewater
State
NJ
Status
Terminated
Country
United States
Event ID
78232
Address
55 Corporate Dr
Code information
Lot #: K5006Y02, Exp 31AUG18
Postal code
08807-1265
Report date
Nov 8, 2017
Product type
Drugs
Recall number
D-0056-2018
Classification
Class III
Recalling firm
Sanofi-Aventis U.S. LLC
Product quantity
422 vials
Termination date
May 13, 2020
Reason for recall
Labeling: Incorrect or Missing Package Insert: authorized generic product was packaged with the incorrect insert for the brand name product Clolar (clofarabine) injection.
Voluntary / mandated
Voluntary: Firm initiated
Product description
Clofarabine injection, 20 mg/20 mL, 20 mL Single-Use Vial, Rx only, Mfd by: Teva Pharmachemle, Swensweg 5, Haarlem, The Netherlands; Mfd for: Winthrop U.S., a business of sanofi-aventis U.S. LLC, Bridgewater, NJ 08807; NDC 0955-1746-01.
Distribution pattern
Nationwide in the USA
Recall initiation date
Oct 13, 2017
Initial firm notification
Letter
Center classification date
Oct 30, 2017

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0056-2018, published Nov 8, 2017. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls